Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial - Giugliano, R P; Pedersen, T R; Park, J G (Lancet, 2017)
et al.